Skip to main content
SpringerLink
Log in

Combination Therapies 2

Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases

  • Book
  • © 1993

Overview

Editors:
  1. Enrico Garaci

    1. University of Rome “Tor Vergata”, Rome, Italy

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Allan L. Goldstein

    1. The Institute for Advanced Studies in Immunology and Aging, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (30 chapters)

  1. Front Matter

    Pages i-x
    Download chapter PDF

  2. Mechanism of Action and Rationale for the Use of Biological Response Modifiers, Differentiating Agents and Nucleoside Analogues in Combination

    1. Cytokine Synergy in Immunotherapy

      • John W. Hadden, Piotr Malec, Anutosh Saha, Elba M. Hadden
      Pages 1-10

    2. Monitoring Combination Therapy Trials: New Challenges for the Clinical Laboratory

      • Jeffrey L. Rossio, Helen C. Rager, Carol S. Goundry, Walter J. Urba
      Pages 11-21

    3. IL-2-Based Consolidative Immunotherapy after Autologous Bone Marrow Transplantation

      • Alexander Fefer, Mark C. Benyunes, Carl Higuchi, Andrea York, Celso Massumoto, Catherine G. Lindgren et al.
      Pages 23-29

    4. Tumor Immunogenicity Induced by the Local Occurrence of Il-2

      • Federica Cavallo, Francesco Di Pierro, Mirella Giovarelli, Alessandra Vacca, Alberto Gulino, Antonella Soppacciaro et al.
      Pages 31-37

    5. Thymosin α1: Chemistry, Mechanism of Action and Clinical Applications

      • Allan L. Goldstein
      Pages 39-48

    6. Combination Therapy with Thymosin α1 and Cytokines in the Treatment of Cancer and Infectious Diseases

      • Enrico Garaci, Antonio Mastino, Francesca Pica, Cartesio Favalli
      Pages 49-60

    7. Effect of Thymosin α 1 on Cocaine-Induced Inhibition of T-Cell Dependent Murine Immune Response

      • Giampietro Ravagnan, Roberto Falchetti, Paolo Di Francesco, Roberta Gaziano, Giulia Lanzilli, Cartesio Favalli et al.
      Pages 61-66

    8. Regulation of Gene Expression by Interferons

      • Santo Landolfo, Marisa Gariglio, Mirella Gaboli, David Lembo, Cristina Mana, Paola Foresta et al.
      Pages 67-70

    9. Interactions between Tumor Necrosis Factor Alpha and Glucocorticoid Hormones in the Regulation of Tumor Cell Growth in Vitro

      • Ildo Nicoletti, Graziella Migliorati, M. Cristina Pagliacci, Fausto Grignani, Carlo Riccardi
      Pages 71-79

    10. Behavioural, Pyrogenic and Electrocortical Effects of Tumor Necrosis Factor - Alpha Given Intracerebrally in Rats

      • G. B. De Sarro, D. Rotiroti, G. Nistrico
      Pages 81-86

    11. Biological Significance and Therapeutic Potential of Tumor-Associated Leukocytes

      • Alberto Mantovani, Barbara Bottazzi, Silvano Sozzani, Giuseppe Peri, Paola Allavena, Annunciata Vecchi et al.
      Pages 87-94

    12. Septic Shock Pathophysiology: Focus on Therapeutic Approach

      • Giancarlo Palmieri, Giuseppe Nicoletti, Silvia Cantoni, Lucio Bucci
      Pages 95-103

    13. Differentiating Agents and Cancer Therapy. Role of Cellular Lipid Peroxidation and its Product 4-Hydroxynonenal in the Control of Cell Proliferation and Differentiation

      • Vito M. Fazio, Giuseppina Barrera, Roberto Muraca, Monica Rinaldi, Silvia A. Ciafrè, Marzia Lazzari et al.
      Pages 105-114

    14. Inhibition of HIV Replication and Enhancement of Immune Functions by the Acyclic Nucleoside Phosphonate 9-(2-Phosphonyl-Methoxyethyl)Adenine (PMEA)

      • C. F. Perno, V. Del Gobbo, J. Balzarini, E. Balestra, G. Milanese, S. Aquaro et al.
      Pages 115-122

    15. Modulation of Inflammatory Cytokines by a Receptor Antagonist, Autoantibodies, and Fever

      • Klaus Bendtzen, Morten B. Hansen, Morten Svenson
      Pages 123-134

  3. Combination Chemotherapy and BRM Therapy in the Treatment of Cancer

    1. Cancer Immunochemotherapy: Preliminary Studies with Triazene Compounds

      • Grazia Graziani, Stefania D’Atri, Anna Giuliani, Annibale Franchi, Daniela Piccioni, Giuseppe Papa et al.
      Pages 135-147

    2. Thymosin α1 and α-Inteferon with Cisplatin and Etoposide in Advanced Non-Small-Cell Lung Cancer: A Phase II Study

      • Massimo Lopez, Giovanni Bonsignore, Modesto D’Aprile, Cartesio Favalli, Marina Della Giulia, Luigi Di Lauro et al.
      Pages 149-153

    3. Combination of Chronic Indomethacin and Intermittent IL-2 Therapy in the Treatment of Disseminated Cancer

      • Peeyush K. Lala, Nahla Al-Mutter, Ranjit Parhar, Mary Nel Saarloos, Vivien Bramwell, William C. Mertens et al.
      Pages 155-165

    4. Combination Chemotherapy and Cytokines in the Treatment of Advanced Primary Lung Cancer: Results of a Controlled Clinical Trial

      • G. Sergio Del Giacco, Giovanni Mantovani, Paola Lai, Emiliano Turnu, Francesca Locci, Anna Carla Scanu et al.
      Pages 167-170
Back to top

Keywords

About this book

The 2nd International Symposium on Combination Therapies brought together several hundred of the leading researchers, scientists and clinicians in this area to discuss new and emerging uses for biological response modifiers (BRM's) in the treatment of cancer and infectious diseases. The meeting was held during May 1-3, 1992 in Acireale, Sicily (Italy). It was hosted by Professor G. Nicoletti CU. of Catania) and organized by the Institute for Advanced Studies in Immunology and Aging (Washington, D. C. ) in collaboration with the University of Rome "Tor Vergata," the University of Catania and The George Washington University Medical Center. The synergy exhibited between BRM's and conventional therapies including bone marrow and other lymphoid cell transplants is a rapidly expanding area with significant promise for the treatment of human diseases. Advances in this area of biomedicine are leading to the rapid development of new therapeutic approaches that are being applied clinically as both primary and adjuvant therapy to enhance the effectiveness of conventional treatments. The 2nd International Symposium on Combination Therapy provided a setting for the exchange of new scientific information regarding the emerging uses for BRM's alone or in combination with conventional therapies. The 1st International Symposium on Combination Therapies was held in 1991 in Washington, D. C.

Editors and Affiliations

  • University of Rome “Tor Vergata”, Rome, Italy

    Enrico Garaci

  • The Institute for Advanced Studies in Immunology and Aging, USA

    Allan L. Goldstein

Bibliographic Information

  • Book Title: Combination Therapies 2

  • Book Subtitle: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases

  • Editors: Enrico Garaci, Allan L. Goldstein

  • DOI: https://doi.org/10.1007/978-1-4615-2964-4

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 1993

  • Hardcover ISBN: 978-0-306-44589-7Published: 31 October 1993

  • Softcover ISBN: 978-1-4613-6289-0Published: 24 October 2012

  • eBook ISBN: 978-1-4615-2964-4Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: X, 256

  • Topics: Infectious Diseases, Immunology, Pharmacology/Toxicology

  • Industry Sectors: Biotechnology, Health & Hospitals, Pharma

Publish with us

Policies and ethics

Back to top

Search

Navigation